Abstract：Objective: To investigate the effect of cell activation factor expression on disease progression and secondary venous thromboembolism in patients with malignant lymphoma.Methods: Between January 2016 and December 2018, 30 cases of malignant lymphoma patients as research group in our hospital, in the same period health check-up 30 cases as control group, the comparative analysis research group and the control group before and after the treatment serum soluble thrombus regulatory proteins (sTM), the surface of the whole blood neutrophils CD11b factor and platelet CD62p factor on the surface level.Results: The levels of sTM, CD11b and CD62p in the study group before treatment were significantly higher than those in the study group and control group (P<0.05), and the levels of each factor were significantly lower after treatment than before treatment, with statistically significant differences in the group (P<0.05), but no statistically significant differences in the levels of each factor after treatment compared with the control group (P>0.05).Conclusion: Endothelial cell injury, abnormal activation of neutrophils and platelet surface factors are likely to lead to thromboembolism, disease progression and secondary venous thromboembolism in patients with malignant lymphoma.
吕乃武, 王红梅, 刘福庆, 周金旭, 刘心平, 李磊. 恶性淋巴瘤患者细胞活化因子的表达及对疾病进展的影响[J]. 河北医学, 2019, 25(12): 2042-2045.
LV Naiwu, WANG Hongmei, LIU Fuqing, et al. Expression of Cell Activation Factor in Patients with Malignant Lymphoma and its Effect on Disease Progression. HeBei Med, 2019, 25(12): 2042-2045.
2019, Vol. 25 
冀公网安备13080202000677号